Skip to main content
Top
Published in: The Journal of Headache and Pain 1/2015

Open Access 01-12-2016 | Short report

Caffeine discontinuation improves acute migraine treatment: a prospective clinic-based study

Authors: Mi Ji Lee, Hyun Ah Choi, Hanna Choi, Chin-Sang Chung

Published in: The Journal of Headache and Pain | Issue 1/2015

Login to get access

Abstract

Background

Caffeine has both excitatory and vasoconstrictive effects on central nervous system. Caffeine use might be associated with development and chronification of migraine. We aimed to evaluate the effect of caffeine cessation on the acute treatment of migraine.

Methods

We prospectively recruited migraine patients who consumed caffeine drinks daily and instructed them to discontinue their caffeine intake. Triptans were prescribed for acute treatment. Patients were followed up after at least two weeks after screening and evaluated the efficacy of acute treatment with the migraine assessment of current therapy (Migraine-ACT) questionnaire. Excellent efficacy was defined as Migraine-ACT score of 4. Chronic migraine, body mass index, allodynia, depression, anxiety, antiemetic use, and use of prophylactic medication were included in the multivariate analysis if the univariate p < 0.2.

Findings

Among 108 patients included, 36 completely discontinued their caffeine intake (abstinence group). The efficacy of acute treatment was assessed at median 34.5 days (interquartile range, 28–89) after the screening. Twenty-six patients (72.2 %) in the abstinence group and 29 (40.3 %) in the non-abstinence group reported an excellent efficacy (p = 0.002). The abstinence group also showed a trend toward greater reduction of headache impact test-6 (HIT-6) scores (p = 0.085). Caffeine abstinence was independently associated with an excellent efficacy of acute treatment (multivariate odds ratio, 3.2; 95 % confidence interval, 1.2–8.4; p = 0.018) after controlling for covariates.

Conclusions

Caffeine abstinence is associated with better efficacy of acute migraine treatment. Our uncontrolled study results encourage a further confirmatory study on this issue.
Literature
2.
go back to reference Hering-Hanit R, Gadoth N (2003) Caffeine-induced headache in children and adolescents. Cephalalgia Int J Headache 23(5):332–335CrossRef Hering-Hanit R, Gadoth N (2003) Caffeine-induced headache in children and adolescents. Cephalalgia Int J Headache 23(5):332–335CrossRef
3.
go back to reference Scher AI, Stewart WF, Lipton RB (2004) Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology 63(11):2022–2027CrossRefPubMed Scher AI, Stewart WF, Lipton RB (2004) Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology 63(11):2022–2027CrossRefPubMed
6.
go back to reference Ward N, Whitney C, Avery D, Dunner D (1991) The analgesic effects of caffeine in headache. Pain 44(2):151–155CrossRefPubMed Ward N, Whitney C, Avery D, Dunner D (1991) The analgesic effects of caffeine in headache. Pain 44(2):151–155CrossRefPubMed
8.
go back to reference Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51(1):83–133PubMed Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51(1):83–133PubMed
9.
go back to reference Sigmon SC, Herning RI, Better W, Cadet JL, Griffiths RR (2009) Caffeine withdrawal, acute effects, tolerance, and absence of net beneficial effects of chronic administration: cerebral blood flow velocity, quantitative EEG, and subjective effects. Psychopharmacology 204(4):573–585. doi:10.1007/s00213-009-1489-4 CrossRefPubMedPubMedCentral Sigmon SC, Herning RI, Better W, Cadet JL, Griffiths RR (2009) Caffeine withdrawal, acute effects, tolerance, and absence of net beneficial effects of chronic administration: cerebral blood flow velocity, quantitative EEG, and subjective effects. Psychopharmacology 204(4):573–585. doi:10.​1007/​s00213-009-1489-4 CrossRefPubMedPubMedCentral
10.
go back to reference Headache Classification Committee of the International Headache S (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia Int J Headache 33(9):629–808. doi:10.1177/0333102413485658 CrossRef Headache Classification Committee of the International Headache S (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia Int J Headache 33(9):629–808. doi:10.​1177/​0333102413485658​ CrossRef
11.
go back to reference Barone JJ, Roberts HR (1996) Caffeine consumption. Food Chem Toxicol Int J Published British Ind Biol Res Assoc 34(1):119–129CrossRef Barone JJ, Roberts HR (1996) Caffeine consumption. Food Chem Toxicol Int J Published British Ind Biol Res Assoc 34(1):119–129CrossRef
12.
go back to reference Chu MK, Im HJ, Ju YS, Yu KH, Ma HI, Kim YJ, Kim J, Lee BC (2009) Validity and reliability assessment of Korean headache impact test-6 (HIT-6). J Korean Neurol Assoc 27(1):1–6 Chu MK, Im HJ, Ju YS, Yu KH, Ma HI, Kim YJ, Kim J, Lee BC (2009) Validity and reliability assessment of Korean headache impact test-6 (HIT-6). J Korean Neurol Assoc 27(1):1–6
15.
go back to reference Gladstone JP, Dodick DW (2004) Acute Migraine: Which Triptan? Pract Neurol 4(1):6–19CrossRef Gladstone JP, Dodick DW (2004) Acute Migraine: Which Triptan? Pract Neurol 4(1):6–19CrossRef
16.
go back to reference Dowson AJ, Tepper SJ, Baos V, Baudet F, D’Amico D, Kilminster S (2004) Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire. Curr Med Res Opin 20(7):1125–1135. doi:10.1185/030079904125004079 CrossRefPubMed Dowson AJ, Tepper SJ, Baos V, Baudet F, D’Amico D, Kilminster S (2004) Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire. Curr Med Res Opin 20(7):1125–1135. doi:10.​1185/​0300799041250040​79 CrossRefPubMed
17.
go back to reference Johansson B, Georgiev V, Lindstrom K, Fredholm BB (1997) A1 and A2A adenosine receptors and A1 mRNA in mouse brain: effect of long-term caffeine treatment. Brain Res 762(1-2):153–164CrossRefPubMed Johansson B, Georgiev V, Lindstrom K, Fredholm BB (1997) A1 and A2A adenosine receptors and A1 mRNA in mouse brain: effect of long-term caffeine treatment. Brain Res 762(1-2):153–164CrossRefPubMed
21.
go back to reference Bendtsen L, Munksgaard S, Tassorelli C, Nappi G, Katsarava Z, Lainez M, Leston J, Fadic R, Spadafora S, Stoppini A, Jensen R, Consortium C (2014) Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia Int J Headache 34(6):426–433. doi:10.1177/0333102413515338 CrossRef Bendtsen L, Munksgaard S, Tassorelli C, Nappi G, Katsarava Z, Lainez M, Leston J, Fadic R, Spadafora S, Stoppini A, Jensen R, Consortium C (2014) Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia Int J Headache 34(6):426–433. doi:10.​1177/​0333102413515338​ CrossRef
Metadata
Title
Caffeine discontinuation improves acute migraine treatment: a prospective clinic-based study
Authors
Mi Ji Lee
Hyun Ah Choi
Hanna Choi
Chin-Sang Chung
Publication date
01-12-2016
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2015
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-016-0662-5

Other articles of this Issue 1/2015

The Journal of Headache and Pain 1/2015 Go to the issue